// App-Quantinova.ai

CTIM-19 : RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT

Researchers

Presenter

  • Manmeet Ahluwalia

Principal Investigators

  • Atulya Khosla

  • Yasmeen Rauf

  • David Peereboom

  • Patrick Y Wen

  • David A Reardon

Medical Centers

  • Dana-Farber Cancer Institute, BOSTON, MA, USA

  • Cleveland Clinic - Richard E. Jacobs Health Center, Cleveland, OH, USA

  • Miami Cancer Institute, Baptist Health South Florida, Miami, FL

  • University of North Carolina, North Carolina, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • O-6-methylguanine DNA methyltransferase

Drug/Treatment

  • Bevacizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved